Prevention of Colorectal Cancer Through Multiomics Blood Testing

ID#: NCT04369053

Age: 45 - 85 years

Gender: All

Healthy Subjects: Accepts Healthy Volunteers

Recruitment Status: Recruiting

Start Date: May 20, 2020

End Date: July 30, 2021

Contact Information:
Chuanbo Xu, PhD
650-762-9937
Staci McAdams
Summary: The PREEMPT CRC study is a prospective multi-center observational study to validate a blood-based test for the early detection of colorectal cancer by collecting blood samples from average-risk participants who will undergo a routine screening colonoscopy.
Eligibility: Key Inclusion Criteria

1. 45-85 years of age

2. Willing to undergo a standard-of-care screening colonoscopy

3. Able and willing to provide a blood sample

4. Able and willing to sign informed consent Key Exclusion Criteria

1. Known hereditary gastrointestinal cancer syndrome (for example, hereditary non-polyposis CRC syndrome (HNPCC) or Lynch syndrome, or familial adenomatous polyposis (FAP)

2. Personal history 2.1 CRC or colorectal adenoma 2.2 Inflammatory bowel disease (IBD), including chronic ulcerative colitis (CUC) and crohn's disease (CD) 2.3 Colonoscopy in the 9 years preceding enrollment 2.4 Stool DNA testing in the 2 years preceding enrollment 2.5 Symptoms of lower gastrointestinal tract disease warranting colonoscopic evaluation

3. A medical condition which, in the opinion of the Investigator, should preclude enrollment in the study

4. Participated or currently participating in a clinical research study in which an experimental medication has been administered during the 60 days up to and including the date of providing informed consent or may be administered through the time of the colonoscopy